{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:15:49Z","timestamp":1793420149297,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>To assess the clinical outcomes and evaluate Freedom from Introduction or Switching of Systemic Treatment (FISST) in patients with oligometastatic (OM) and oligoprogressive (OP) disease undergoing stereotactic body radiotherapy (SBRT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the need to introduce or switch the systemic line of treatment for any reason or inability to provide systemic treatment when needed because of poor performance status (PS) (Eastern Cooperative Oncology Group PS \u22653) or other reasons. OS was a secondary outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>A total of 200 patients were included. The median age was 60 (IQR, 49-70) years. The most common primary tumors were colorectal (61, 30.5%), breast (30, 15.0%), lung (28, 14.0%), head and neck (23, 11.5%), and prostate (16, 8.0%). A total of 257 metastatic lesions were treated. Bone was the most frequent site (115, 44.7%), followed by the liver (55, 21.4%), lung (44, 17.1%), lymph nodes (25, 9.7%), and adrenal glands (11, 4.3%). The median follow-up was 15 months. FISST at 1 and 2 years were 52% and 39%, respectively. LC at 1 and 2 years were 86.3% and 80%, respectively. OS at 1 and 2 years were 76.5% and 64.8%, respectively. Grade III toxicity was reported in 1.5% of patients overall, with no observed grade IV or V toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>SBRT is effective and safe for treating OM and OP solid cancers, prolonging FISST and potentially delaying systemic treatments, particularly in settings with limited access to advanced therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-25-00004","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:59:36Z","timestamp":1759521576000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-8398","authenticated-orcid":true,"given":"Abdulla","family":"Alzibdeh","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wahbeh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha Abu","family":"Taha","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Qambar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelatif","family":"Al Mousa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Khader","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-6789","authenticated-orcid":true,"given":"Fawzi","family":"Abuhijla","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-3182","authenticated-orcid":true,"given":"Ayah","family":"Erjan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoud","family":"Alnsour","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-9131","authenticated-orcid":true,"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1224","authenticated-orcid":true,"given":"Baha","family":"Sharaf","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine, Suez University, Suez, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-464X","authenticated-orcid":true,"given":"Sara","family":"Mheid","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":true,"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-770X","authenticated-orcid":true,"given":"Wafa","family":"Asha","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33587"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.465"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2474"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00380-6"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.44"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.04.003"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.025"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-536"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.09.002"},{"key":"e_1_3_4_12_2","article-title":"Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries","author":"Kraus RD","unstructured":"Kraus RD, Weil CR, Abdel-Wahab M: Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries. JCO Glob Oncol 10.1200\/GO.22.00215","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.004"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.04.004"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.025"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2308"},{"key":"e_1_3_4_22_2","volume-title":"The Cancer Burden in Low- and Middle-Income Countries and How It Is Measured","author":"Institute of Medicine (US) Committee on Cancer Control in Low- and Middle-Income Countries","year":"2007","unstructured":"Institute of Medicine (US) Committee on Cancer Control in Low- and Middle-Income Countries, Sloan FA, Gelband H: The Cancer Burden in Low- and Middle-Income Countries and How It Is Measured. Washington, DC, National Academic Press, 2007"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-018-0776-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1486040"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20181026"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13501"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.12.018"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1533033818794936"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02352-4"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34017"},{"key":"e_1_3_4_31_2","first-page":"1","article-title":"Indirect cell death and the LQ model in SBRT and SRS","volume":"7","author":"Song CW","year":"2020","unstructured":"Song CW, Terezakis S, Emami B, et al: Indirect cell death and the LQ model in SBRT and SRS. J Radiosurgery SBRT 7:1, 2020","journal-title":"J Radiosurgery SBRT"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.02.038"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:59:37Z","timestamp":1759521577000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1200\/GO-25-00004"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00004","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500004"}}